Neogen Corp (NG2.DU) Seasonal Returns Chart - Yahoo Finance
The Yahoo Finance page for Neogen Corp (NG2.DU) displays seasonal returns information. It shows the average monthly price return for the stock over various periods (3Y, 5Y, 10Y, 20Y, All) from 2024 to 2026. The stock was trading at 10.14 EUR, down 3.20% at the close on November 12.
Neogen Corp (NG2.DU) Seasonal returns chart - Yahoo Finance
This page from Yahoo Finance displays the seasonal returns chart for Neogen Corp (NG2.DU). It shows the average monthly price return for the company from 2024 to 2026. The current delayed quote for Neogen Corp in Dusseldorf is 10.30 EUR, down 1.72%.
What Investors Overlooked Before Neogen's 84% Run
Neogen (NasdaqGS:NEOG) saw an 83.8% return over the past year, prompting an analysis of what signals in late 2025 might have justified investing in the loss-making diagnostics group. Despite initial bearish views, Q1 FY 2027 results showed revenue growth, though a net loss was reported, challenging the rising margin thesis. The current share price of US$11.76 suggests that the market may not yet fully account for Neogen's potential to convert its large installed base and analytics platform into higher recurring consumable usage and stronger long-term margins.
Form 144 NEOGEN CORP For: 7 November By Investing.com
This article from Investing.com announces the filing of Form 144 for NEOGEN CORP, pertaining to activities on November 7. Form 144 is a notice of the intent to sell restricted securities. The article provides the title and links to general market information on Investing.com.
Form 144 NEOGEN CORP For: 7 November By Investing.com
This article reports on the filing of Form 144 for NEOGEN CORP (NEOG) on November 7, 2026. Form 144 indicates an intent to sell restricted or control securities. The article provides the title of the filing and mentions the company's stock symbol along with a slight dip in its price.
Neogen Stock Gets A Lift From Earnings Beat And Higher Fiscal 2027 Guidance
Neogen reported better-than-expected Q1 fiscal 2027 adjusted earnings and revenue, along with increased guidance for full-year revenue and adjusted EBITDA. This positive update highlights improved gross profit, stronger cash flow, and reduced debt, indicating better cost control and a more resilient balance sheet for the company. Despite ongoing regulatory scrutiny related to an FDA warning and a securities investigation, these operational improvements are expected to bolster Neogen's financial resilience.
Neogen (NEOG) Up 6.7% Since Last Earnings Report: Can It Continue?
Neogen (NEOG) shares have increased by 6.7% since its last earnings report, outperforming the S&P 500. The company reported strong Q1 fiscal 2027 results, beating revenue and earnings estimates, and raised its fiscal 2027 guidance. Despite positive financial performance, analyst estimates have trended downward, leading to a Zacks Rank #3 (Hold) for the stock.
Neogen CSO Jeremy Yarwood sells $114,676 in stock By Investing.com
Neogen's Chief Scientific Officer, Jeremy Yarwood, sold 9,051 shares of company stock for $114,676 on November 4, 2026, after acquiring 16,207 shares via vested restricted stock units on November 3, 2026. The stock has seen a significant surge in the past year and InvestingPro analysis suggests it is overvalued. This transaction follows a strong first quarter for Neogen, which reported adjusted earnings and revenue exceeding expectations, leading to raised full-year guidance.
Form 4 Neogen Corporation: Jeremy Yarwood (Chief Scientific Officer) For: 3 November
This article reports on a Form 4 filing for Neogen Corporation, indicating that Jeremy Yarwood, the Chief Scientific Officer, made a transaction on November 3rd. Form 4 filings are regulatory documents detailing changes in ownership of company stock by insiders. The article was published on November 5, 2026, at 10:06.
Zoetis's offer to divest Australian assets accompanies Neogen (NEOG)'s pending Genomics sale.
Neogen Corporation (NEOG) announced that the regulatory review for its sale of the global Genomics business to Zoetis Inc. is expected to conclude in early 2027. This timeline follows Zoetis's offer to divest certain Australian assets to facilitate regulatory clearance from the Australian Competition and Consumer Commission and the New Zealand Commerce Commission. The transaction, initially announced on March 2, 2026, remains subject to customary closing conditions and regulatory approvals.
A 9,051-share sale at Neogen (NEOG) followed stock vesting and 7,156 shares withheld for taxes.
Neogen's Chief Scientific Officer, Jeremy Yarwood, sold 9,051 shares of NEOG at $12.67 per share on November 4, 2026. This sale followed the vesting of 16,207 Restricted Stock Units (RSUs) on November 3, 2026, where 7,156 shares were withheld for taxes. The transaction was reported without a Rule 10b5-1 plan, resulting in a net sale of 9,051 shares.
After stock vesting, Neogen (NEOG) officer Jeremy M. Yarwood proposes selling 9,051 shares.
Neogen officer Jeremy M. Yarwood has proposed selling 9,051 common shares, valued at approximately $114,637.14, which were acquired through restricted stock vesting on November 1, 2026. The proposed sale date is November 4, 2026, and the transaction will be handled by Fidelity Brokerage Services LLC. This information was reported via a Form 144 SEC filing.
UBS's healthcare conference will include Neogen in Palm Beach Gardens.
Neogen Corporation (NASDAQ: NEOG) announced its participation in the 2026 UBS Global Healthcare Conference, scheduled for Tuesday, November 10, in Palm Beach Gardens, Florida. The company, a leader in global food security and human/animal well-being, will present at the event. This announcement highlights Neogen's ongoing engagement in industry conferences to discuss its strategic direction and solutions.
As of October 1, 2026, Neogen (NEOG) HR chief Kevin M. Burke held 12,929 shares directly.
Neogen's Chief HR Officer, Kevin M. Burke, reported holding 12,929 shares of the company's common stock directly as of October 1, 2026. This information was disclosed in a Form 3 SEC filing on October 30, 2026, indicating an initial statement of beneficial ownership. The filing notes that this is a moderate impact with a neutral sentiment, reflecting an ownership position rather than a transaction.
Vested stock grants deliver 1,211 Neogen (NEOG) shares to its animal health VP at $12.21 each.
Neogen Corp.'s VP of Animal Health, Gregory S. Hastings, received 1,211 common shares from the vesting and settlement of restricted stock units on October 29, 2026. The shares were valued at $12.21 each. A total of 337 shares were withheld for tax liability or exercise price payment, leaving his reported RSU position at zero.
After a stock grant vested, Neogen (NEOG) director Catherine E. Woteki holds 29,507 shares.
Neogen director Catherine E. Woteki received 1,776 shares of common stock after 1,776 restricted stock units (RSUs) vested on October 29, 2026. Following this transaction, her direct holdings in NEOGEN CORP common stock increased to 29,507 shares. The transaction, valued at approximately $22,000 based on a price of $12.21 per share, was reported in an SEC Form 4 filing.
After receiving 1,776 shares, Neogen (NEOG) director holds 31,211 shares directly.
Neogen Corp. (NEOG) director Rafael A. Rodriguez had 1,776 Restricted Stock Units (RSUs) vest and settle on October 29, 2026, converting them into an equal number of common shares. Following this transaction, his direct common-stock holdings increased to 31,211 shares, while his RSU position became zero. This insider trading activity was reported in a Form 4 filing with the SEC.
Form 4 Neogen Corporation: Catherine E. Woteki (Director) For: 1 October
This article reports on a Form 4 filing for Neogen Corporation, indicating that Catherine E. Woteki, a director, made a transaction on October 1st. The filing pertains to insider trading activity at Neogen Corporation (NEOG). The article itself provides minimal detail beyond the filing's existence and the associated company and individual.
Form 4 Neogen Corporation: Rafael A. Rodriguez (Director) For: 29 October By Investing.com
This article reports on a Form 4 filing for Neogen Corporation, detailing insider transaction information for Director Rafael A. Rodriguez related to activity on October 29. The filing was published on October 30, 2026.
After receiving 1,776 shares, Neogen (NEOG) director holds 42,892 directly.
Neogen (NEOG) director Jeffrey D. Capello received 1,776 common shares from the vesting and settlement of restricted stock units on October 29, 2026. Following this transaction, Capello directly holds 42,892 common shares. The RSU transaction was reported at a price of $12.21 per share.
After receiving 1,776 shares, Neogen (NEOG) director Gupta holds 38,180 directly.
Neogen director Aashima Gupta received 1,776 common shares from the vesting of restricted stock units (RSUs) on October 29, 2026. Following this transaction, Gupta directly holds 38,180 common shares of Neogen (NEOG). The transaction was reported in an SEC Form 4 filing.
Neogen's VP Gregory Hastings Converts 1,211 RSUs and Withholds 337 Shares on October 29, 2026
Gregory S. Hastings, Vice President of Animal Health at Neogen Corp, converted 1,211 restricted stock units (RSUs) into common shares and withheld 337 shares for tax purposes on October 29, 2026. These transactions, executed at $12.21 per share, resulted in Hastings directly owning 33,449 shares of Neogen Corp common stock. The Form 4 filing, submitted on October 30, 2026, confirmed the RSU settlement and subsequent share adjustments.
Form 144 NEOGEN CORP For: 29 October By Investing.com
This article from Investing.com announces a Form 144 filing for NEOGEN CORP on October 29, 2026. Form 144 is a notice to the SEC of the intent to sell restricted securities. The article provides only this brief notification without further details on the transaction.
A former director plans to sell 16,937 Neogen (NEOG) shares.
Thierry Bernard, a former director of Neogen (NEOG), has filed a notice of proposed sale for 16,937 common shares through Fidelity Brokerage Services LLC. These shares, with an aggregate market value of $206,520.92, were acquired through a cash-paid stock option exercise on October 28, 2026, which is also the approximate sale date. The filing details the transaction and relevant financial metrics.
Neogen Corporation Shareholders Endorse Updated Omnibus Incentive Plan in 2026 Annual Meeting
Neogen Corporation shareholders have approved an Amended and Restated Omnibus Incentive Plan during the company's annual meeting on October 1, 2026. The plan authorizes the issuance of up to 31,350,000 shares for various equity awards, including stock options and restricted stock units, to eligible recipients such as non-employee directors, employees, and named executive officers. This update was reported in an amended Form 8-K/A filed on October 26, 2026.
Shareholders approve a stock-award pool for employees and non-employee directors at Neogen (NEOG).
Neogen Corporation shareholders approved an amended and restated Omnibus Incentive Plan at their annual meeting on October 1, 2026. This plan authorizes the issuance of up to 31,350,000 shares for equity awards to employees and non-employee directors, including various forms such as stock options, restricted stock, and performance stock units. The amendment includes disclosure regarding shareholder approval of this incentive plan as part of an 8-K/A filing.
Neogen Corporation (NEOG) stock price, news, quote and history
Neogen Corporation (NEOG) stock shows a positive YTD and 1-year return, despite a recent after-hours dip. The company operates in food and animal safety, offering diagnostic kits, veterinary instruments, and genomic services through its Food Safety and Animal Safety segments. Analysts maintain a "Buy" rating with a target price of $14.00.
Form 4 Neogen Corporation: Gregory S. Hastings (VP, Animal Health) For: 14 October
This article reports on a Form 4 filing for Neogen Corporation, detailing activity by Gregory S. Hastings, VP of Animal Health, for October 14. The filing is a standard disclosure of insider transactions. Neogen Corporation's stock symbol NEOG is mentioned with a gain of 1.75%.
Form 4 Neogen Corporation: Gregory S. Hastings (VP, Animal Health) For: 14 October
This article reports on a Form 4 filing for Neogen Corporation, specifically concerning Gregory S. Hastings, VP of Animal Health, for transactions made on October 14th. The filing indicates insider activity for the company (NEOG), which saw its stock price increase by 1.75%.
A vested stock grant gives Neogen (NEOG)'s animal health VP 287 common shares.
Neogen Corp's VP, Animal Health, Gregory S. Hastings, acquired 287 common shares after 287 restricted stock units vested on October 14, 2026. An additional 80 common shares were delivered or withheld for tax liability. Following these transactions, Hastings holds 32,575 common shares and 0 restricted stock units.
Form 4 NEOGEN CORP For: Oct 14 Filed by: Hastings Gregory S
Gregory S. Hastings, VP of Animal Health at NEOGEN CORP, filed a Form 4 reporting changes in beneficial ownership of common stock. On October 14, 2026, Hastings acquired 287 shares of common stock upon the vesting and settlement of restricted stock units (RSUs) at a price of $12 per share, and simultaneously disposed of 80 shares at the same price. Following these transactions, Hastings beneficially owns 32,575 shares of NEOGEN CORP common stock directly.
Commercial chief Joe B. Freels reports initial ownership at Neogen (NEOG).
Neogen Corporation (NEOG) has listed Joe B. Freels, their Chief Commercial Officer, as a reporting person in an initial statement of beneficial ownership (Form 3). This SEC filing indicates that Freels does not beneficially own any securities at the time of the statement. The filing was accepted by the SEC EDGAR system on October 21, 2026, at 10:17 AM EDT.
Neogen (NEOG) Is Back In Focus, So What Is Catching Investors' Attention?
Neogen (NEOG) is gaining investor attention after management provided an update on fiscal 2027, projecting revenue growth, improved operating performance, and higher guidance. The company also announced a new food safety technology collaboration. Despite a significant 92.02% one-year total shareholder return, the stock has fallen 13.37% over the last month and shows a 71.34% decline over five years.
Manufacturing SVP holds 28,955 shares directly in Neogen (NEOG).
Neogen Corp. (NEOG) reports that James A. Walter, SVP of Manufacturing, directly holds 28,955 common shares as of October 1, 2026. This information was disclosed in a Form 3 filing, an initial statement of beneficial ownership of securities. The filing indicates a neutral sentiment and a moderate impact, showing only a direct holding transaction.
Ownership is disclaimed for 297 shares held by the son of Neogen (NEOG) science chief Jeremy Yarwood.
Neogen Corp.'s Chief Scientific Officer, Jeremy Yarwood, reported an indirect holding of 297 shares of common stock held by his son on October 1, 2026. Yarwood explicitly disclaims beneficial ownership of these shares, meaning he does not admit to being their beneficial owner for purposes of Section 16 or any other reason. This filing highlights transparency requirements for company insiders regarding stock holdings, even if beneficial ownership is denied.
Form 3 NEOGEN CORP For: Oct 01 Filed by: Yarwood Jeremy
Jeremy Yarwood, Chief Scientific Officer of NEOGEN CORP (NEOG), filed an initial statement of beneficial ownership of securities (Form 3) with the SEC. The filing, dated October 1, 2026, indicates indirect beneficial ownership of 297 shares of common stock through his son. Yarwood disclaims beneficial ownership of these securities.
Form 4 Neogen Corporation: James C. Borel (Director) For: 1 October
This article reports on a Form 4 filing for Neogen Corporation, indicating that James C. Borel, a director, had a transaction on October 1st. Form 4 filings are mandatory documents filed with the SEC whenever there is a material change in the holdings of company insiders. The specific details of the transaction are not provided within this brief news item.
Form 4 Neogen Corporation: James C. Borel (Director) For: 1 October
This article reports on a Form 4 filing for Neogen Corporation, specifically detailing a transaction by Director James C. Borel. The filing date is noted as October 1st.
Form 4 Neogen Corporation: Rafael A. Rodriguez (Director) For: 1 October By Investing.com
This article reports on a Form 4 filing for Neogen Corporation, indicating that Director Rafael A. Rodriguez made a transaction on October 1st. The filing pertains to insider trading activity within the company.
Form 4 Neogen Corporation: Rafael A. Rodriguez (Director) For: 1 October
This article reports on a Form 4 filing for Neogen Corporation, detailing an insider transaction by Director Rafael A. Rodriguez on October 1st. The brief announcement provides the company's stock symbol (NEOG) and indicates a positive stock movement of +1.49%.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neogen Corporation - NEOG
Pomerantz LLP is investigating Neogen Corporation (NASDAQ: NEOG) on behalf of investors regarding potential securities fraud or unlawful business practices. This investigation follows a September 29, 2026 announcement by the FDA concerning a warning letter issued to Neogen. The warning letter was linked to serious infections and deaths in horses caused by a veterinary wound care product, leading to a significant drop in Neogen's stock price.
Securities Fraud Investigation Into Neogen Corporation
Glancy Prongay Wolke & Rotter LLP is continuing its securities fraud investigation into Neogen Corporation (NASDAQ: NEOG) following an FDA warning letter. The FDA linked Neogen's Hycoat product to serious infections and at least 20 horse deaths, citing quality defects and misbranding. Following this news, Neogen's stock fell 7.22%.
Neogen Q1 Fiscal 2027 Revenue Rises 6.5% as Company Raises Outlook
Neogen (NASDAQ: NEOG) reported a 6.5% increase in first-quarter fiscal 2027 revenue to $222.8 million, with core growth of 8.1%. Despite a net loss, Adjusted Net Income and Adjusted EBITDA saw significant gains, leading the company to raise its fiscal 2027 revenue and Adjusted EBITDA outlook. Neogen is also progressing with its Petrifilm manufacturing transition and expects to close the sale of its Genomics business to Zoetis Inc. by the end of December 2026.
Securities Fraud Investigation Into Neogen Corporation
The Law Offices of Frank R. Cruz is continuing its investigation into Neogen Corporation (NASDAQ: NEOG) for possible federal securities law violations. This investigation follows a September 29, 2026 FDA warning linking Neogen's Hycoat product to serious infections and at least 20 horse deaths, leading to a 7.22% stock drop. Shareholders who lost money are encouraged to contact the firm to inquire about potentially pursuing a claim.
Zacks Industry Outlook Highlights ICU Medical, Neogen and Trulieve Cannabis
Zacks Equity Research highlights ICU Medical (ICUI), Neogen (NEOG), and Trulieve Cannabis Corp. (TRLV) as key players in the Medical Products industry, which is experiencing moderate growth driven by innovation, migration to ambulatory care, and robust demand despite cost pressures. The industry faces challenges from tariffs, inflation, and supply-chain friction, but companies like ICU Medical, Neogen, and Trulieve Cannabis are poised for growth through strategic execution and market trends. These companies are recommended as "Buy" or "Strong Buy" based on their individual growth catalysts and financial outlooks.
Neogen CEO Mikheal Nassif buys $6,034 in common stock
Mikheal Nassif, CEO of NEOGEN Corp., recently purchased 505 shares of company stock totaling $6,034. This insider transaction follows a year of significant stock returns and strong Q1 fiscal 2027 results for Neogen, although shares saw a slight decline in the week prior to the purchase. InvestingPro analysis suggests the stock is currently overvalued, despite the positive financial performance.
Neogen CEO Mikheal Nassif buys $6,034 in company stock
Neogen CEO Mikheal Nassif recently purchased 505 shares of the company's common stock for $6,034. This transaction occurred on October 9, 2026, with shares acquired at $11.95 each. The company has a market cap of $2.56 billion and has seen a 96% return over the past year, though InvestingPro analysis suggests the stock is currently overvalued.
Neogen CEO Mikheal Nassif buys $6,034 in company stock
Neogen CEO Mikheal Nassif purchased 505 shares of NEOGEN CORP stock for $6,034 on October 9, 2026, increasing his indirect beneficial ownership to 1,579 shares. This insider transaction comes as Neogen recently reported strong Q1 fiscal 2027 results, surpassing analyst expectations for both earnings and revenue, and raising its full-year guidance. Despite the positive performance, InvestingPro analysis indicates NEOG may be overvalued.
Neogen CEO Mikheal Nassif buys $6,034 in company stock By Investing.com
Neogen CEO Mikheal Nassif purchased 505 shares of NEOGEN CORP (NASDAQ:NEOG) common stock for $6,034 on October 9, 2026, at $11.95 per share. This transaction follows the company's strong Q1 fiscal 2027 results, where it surpassed Wall Street expectations with adjusted earnings of $0.08 per share and revenue of $222.8 million. Despite the stock appearing overvalued by InvestingPro analysis, Neogen has shown consistent core revenue growth and raised its full-year guidance.
Neogen Shifts Focus to Scale Profitable Growth
Neogen Corp. (NASDAQ: NEOG) reported better-than-expected first-quarter fiscal 2027 financial results, with adjusted earnings beating consensus estimates and sales up 6.5% year over year. The company's focus has shifted to scaling fundamentals for more consistent execution and profitable growth, leading to raised fiscal 2027 guidance for both sales and adjusted EBITDA. Despite positive financial results, Neogen's stock fell on Wednesday.